Abbisko Cayman Limited (2256.HK) Stock
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics.
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Peer Comparison
About Abbisko Cayman Limited
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.
Abbisko Cayman Limited is led by CEO Yao-Chang Xu, employs 276 people, headquartered in Shanghai, CN, publicly traded since 2021.
over the past 52 weeks the stock has ranged between $8.34 and $19.78, and currently trades 44.3% below its 52-week high.
Official website: www.abbisko.com